Yemen's Health Minister Opens First Training Course for Pharmaceutical Factory Inspectors

Spread the Word

Yemen’s Minister of Public Health and Population, Qassem Buhaibeh, opened the country’s first intensive training course on Good Manufacturing Practice and the inspection of pharmaceutical production facilities in Aden in May 2026. The course was organised by the national medicines regulator through its training and continuing education department, and its opening week was designed to qualify 40 participants drawn from the authority’s headquarters and its branches in the governorates.

Good Manufacturing Practice, universally shortened to GMP, is the body of rules that governs how medicines are made: how premises are laid out and cleaned, how raw materials are sourced and tested, how batches are documented, how staff are trained, and how a manufacturer proves after the fact that a given batch was produced as intended. It is unglamorous and highly procedural, and it is the difference between a factory that can be trusted to produce a sterile injectable and one that cannot.

The training was aimed squarely at the inspection side of that equation. Regulators do not manufacture medicines; they audit those who do. An inspector needs to be able to walk into a plant, read its batch records, examine its water system and its air handling, question its quality-control laboratory and decide whether the product leaving the site is what the label says it is. Yemen’s regulator has authority on paper to make that judgement. What the war has eroded is the trained staff needed to exercise it consistently across a fragmented country.

That gap has consequences well beyond the factory gate. Yemen’s health system has been running on a mixture of imported medicines, donated supplies and a small domestic manufacturing sector since the conflict began, and oversight of all three has been strained by the division of institutions between rival administrations. Where regulatory capacity thins, substandard and falsified medicines follow. They are cheaper to produce, they look identical on a shelf, and in a market where households are paying out of pocket for treatment they are difficult for patients to detect and expensive for anyone to police.

Aden’s role as the venue matters as much as the syllabus. Yemen’s internationally recognised government has run its ministries from the southern port city since 2015, while Sanaa and much of the north remain under Houthi control, and the country’s regulatory institutions have effectively been duplicated along that line. A medicine registered, inspected or recalled by one administration is not automatically registered, inspected or recalled by the other. That split is one reason a single training cohort, however competent, cannot on its own guarantee that a patient anywhere in Yemen is buying what the packaging claims.

The minister has treated that as a live enforcement problem rather than an abstract one. In the same period he ordered tighter controls aimed at keeping smuggled medicines out of the distribution chain, a recurring difficulty in a country with long coastlines, contested borders and a large informal trade. Smuggled stock bypasses registration, storage and cold-chain requirements entirely, which means that even where the product is genuine there is no assurance it was kept at the right temperature or is still within date by the time it reaches a pharmacy.

Building inspection capacity also has an economic argument behind it. Yemen imports the overwhelming majority of the medicines it consumes, which drains hard currency at a time when the central bank in Aden has been fighting a losing battle to defend the riyal. A domestic pharmaceutical sector capable of producing basic generics to a credible standard would ease part of that pressure. But no serious buyer, and no international agency running a procurement programme, will source from a plant whose regulator cannot certify it. Inspection capability is the precondition for the manufacturing capability, not an afterthought to it.

The course structure suggests the authority understood this as a first instalment rather than a finished project. Forty inspectors in an opening week-long phase is a starting cohort, not a national inspectorate, and GMP competence is normally built through repeated audits under supervision rather than through classroom instruction alone. Whether the programme continued into further phases, and whether the participants were subsequently deployed to inspect operating facilities, is the measure of whether it changed anything.

There is a wider institutional point here as well. Much of what has been written about Yemen’s health sector over the past decade concerns emergency response: cholera, measles, malnutrition, the funding of hospitals and clinics. Regulatory capacity attracts far less attention and almost no dedicated donor money, yet it determines the quality of everything that flows through the system that emergency funding pays for. A country can receive a great deal of medicine and still have a health system that cannot vouch for any of it.

For the regulator itself, running a course of this kind in Aden also served a demonstrative purpose. It signalled that the authority intended to function as a technical body applying international standards, not merely as a licensing office, at a point when Yemeni institutions have been under pressure to show they still work. Whether that intention translated into routine, enforceable inspection across the pharmaceutical market is a question that only sustained follow-through could answer, and that follow-through has been the harder part of every institutional reform attempted in Yemen since the war began.